Lantibiotics are ribosomally synthesized peptides that undergo posttranslational modifications to their mature, antimicrobial form. They are characterized by the unique amino acids lanthionine and methyllanthionine, introduced by means of dehydration of Ser͞Thr residues followed by reaction of the resulting dehydro amino acids with cysteines to form thioether linkages. Two-component lantibiotics use two peptides that are each posttranslationally modified to yield two functionally distinct products that act in synergy to provide bactericidal activity. By using genetic data instead of isolation, a two-component lantibiotic, haloduracin, was identified in the genome of the Gram-positive alkaliphilic bacterium Bacillus halodurans C-125. We show that heterologously expressed and purified precursor peptides HalA1 and HalA2 are processed by the purified modification enzymes HalM1 and HalM2 in an in vitro reconstitution of the biosynthesis of a two-component lantibiotic. The activity of each HalM enzyme is substratespecific, and the assay products exhibit antimicrobial activity after removal of their leader sequences at an engineered Factor Xa cleavage site, indicating that correct thioether formation has occurred. Haloduracin's biological activity depends on the presence of both modified peptides. The structures of the two mature haloduracin peptides Hal␣ and Hal␤ were investigated, indicating that they have similarities as well as some distinct differences compared with other two-component lantibiotics.
D
ue to the rapid spread of multiple-drug-resistant bacterial strains, antimicrobial peptides are being investigated as a potential new source of antibiotics to treat infections. The lantibiotic group of bacteria-derived antimicrobial peptides possess high antibacterial activity against Gram-positive bacteria, including drug-resistant strains (1, 2) . Over 45 members have been identified in the lantibiotic family (3) , with the most studied lantibiotic, nisin, used world wide in food preservation for Ͼ40 years (1) . All lantibiotics contain lanthionine (Lan) and͞or methyllanthionine (MeLan) residues and also typically the unsaturated amino acids dehydroalanine (Dha) and dehydrobutyrine (Dhb). These structural motifs are the bases for their biological activity as well as their family name (4) .
Lantibiotics are ribosomally synthesized as precursor peptides (prepeptides) that are subjected to posttranslational modifications to produce the active, mature compounds (2, 3) . The prepeptide contains an N-terminal leader sequence that does not undergo posttranslational modification. The exact role of this leader sequence is still unclear but it seems to be required for modification of the C-terminal structural region and is removed by proteolysis to produce the mature lantibiotic (4-7). The dehydro amino acids are introduced by means of dehydration of serine and threonine residues located in the structural region of the prepeptide. Lanthionine and methyllanthionine rings are then generated by intramolecular additions of cysteine residues to these ␣,␤-unsaturated amino acids.
A growing class of two-component lantibiotic systems utilize two peptides that are each posttranslationally modified to an active form and act in synergy to provide antibacterial activity (8) . Dehydration and cyclization of the prepeptides to form lanthionine bridges in these systems are likely performed by bifunctional LanM proteins. In most cases, the sequence similarity of the two prepeptides is rather low (Ϸ25%), and so two different enzymes are thought to be used for the posttranslational modification of each peptide (9) . The exception is cytolysin, a two-component lantibiotic that is processed by a single LanM enzyme (10) . In this case, the sequence homology of the two peptide substrates is much higher at Ϸ90%.
The best-studied two-component lantibiotic, lacticin 3147, consists of the modified peptides LtnA1 and LtnA2 (11) . Because the designation LtnA1 and LtnA2 also refers to the unmodified prepeptides, we prefer to use in this report the designation Ltn␣ and Ltn␤ for the mature, active components. The posttranslational modification of each prepeptide is believed to be catalyzed by two separate bifunctional enzymes, LtnM1 and LtnM2, based on genetic data in which deletion of either LanM gene results in abrogation of bioactive material (9) . To date, in vitro activity of LtnM1 or LtnM2 has not been demonstrated. A recent study on the mode of action of lacticin 3147 demonstrated that Ltn␣ binds to the peptidoglycan precursor lipid II (12), a result that was anticipated because of the structural similarity between Ltn␣ and mersacidin, which also binds to lipid II (13) . However, in order for lacticin 3147 to inhibit cell wall biosynthesis and form small pores in the cell membrane, Ltn␤ is also necessary, leading to a proposed model in which the lipid II:Ltn␣ complex recruits Ltn␤ to form an active complex (12, 14) .
The mechanisms governing substrate recognition and specificity in two-component lantibiotic systems that use two modification enzymes are of great interest because it requires each LanM protein to discriminate between the two prepeptides present in the cell. In vitro reconstitution of a two-component lantibiotic biosynthetic system would allow questions about their recognition and specificity to be answered. This understanding could be used to develop novel lantibiotics based on designing peptide sequences that can be site-specifically modified to yield new products. Given the synergy observed among twocomponent lantibiotics, which display similar or higher activity than the best single-component lantibiotic nisin (14) , the possibility of engineering new lantibiotics with therapeutic potential is even greater for these systems.
In this article, we describe a two-component lantibiotic from the Gram-positive bacterium Bacillus halodurans C-125. This alkaliphilic bacterium grows at pH Ͼ9.0 (15), suggesting that the lantibiotic it produces will be stable at alkaline pH, unlike, for instance, nisin (16) . This anticipated stability could provide an important advantage or complement to other lantibiotic systems. We here report the successful in vitro reconstitution of the biosynthesis of this lantibiotic (which we have termed haloduracin), as well as examination of the substrate specificity of the modification enzymes, haloduracin's synergistic antimicrobial activity, and the structures of the two mature products.
Results
Bioinformatics Discovery of the Two-Component Lantibiotic Haloduracin. During a search for analogs of the lantibiotic mersacidin, we found a gene annotated in the fully sequenced genome of the Gram-positive bacterium B. halodurans C-125 as a mersacidin precursor (BAB04173) (15) . This strain has not previously been reported to produce a lantibiotic. The gene that we termed halA1 encodes a peptide of 69 residues, with a 41-residue leader sequence of the double-glycine type that is likely removed by a protease resulting in a 28-residue active peptide (Fig. 1) . The HalA1 peptide is predicted to have 34% sequence identity with the precursor peptide for mersacidin. Further analysis of the surrounding DNA sequence identified the divergent halA2 gene immediately 5Ј of halA1. The encoded peptide has been annotated as cytolysin precursor (BAB04172) (15) . This peptide, termed HalA2 herein, contains 65 residues, 35 of which likely comprise the leader sequence based on a predicted doubleglycine cleavage signal at residues Gly34Ser35. The two prepeptides HalA1 and HalA2 have 22.9% sequence identity to each other. HalA1 has significant sequence identity (40-50%) with peptides from other two-component systems, including LtnA1 (lacticin 3147) (11) , PlwA␣ (plantaricin W) (17) , and SacA␣ (staphylococcin C55) (18) (Fig. 1) . However, the peptide contains a significantly longer leader peptide compared with its homologs. HalA2 exhibits similarity (35-40% identity) to PlwA␤ (plantaricin W), CylL-A L and CylL-A S (cytolysin), and LtnA2 (Fig. 1) . Two lanM genes, designated halM1 and halM2, were found flanking the two halA genes and were predicted to encode the enzymes that perform the posttranslational modification of HalA1 and HalA2. The HalM proteins exhibit 25% sequence identity to each other and other LanM proteins from both two-component and single component lantibiotic systems. The leader sequence of the modified HalA peptides is likely removed by a bifunctional transport protein designated HalT that was also encoded in the gene cluster. HalT contains a N-terminal proteolytic region, six transmembrane regions, and an ATP binding domain and shares homology with the ATPbinding cassette (ABC) family of proteins (19) .
Production of Haloduracin by B. halodurans C-125. Haloduracin production was observed when B. halodurans C-125 was grown on modified nutrient broth for Ͼ90 h to promote sporulation, which often induces antibiotic production. Cells and spores were removed by centrifugation and the supernatant containing the haloduracin peptides was collected. Analysis of the cell-free supernatant by MALDI-TOF MS showed two products with masses of 2,332 Da (M ϩ H) and 3,046 Da (M ϩ H). When applied to a Lactococcus lactis CNRZ 117 indicator strain, a zone of growth inhibition was produced. These results strongly suggest the isolation of active haloduracin from the producer strain under these conditions.
Reconstitution of Haloduracin Production. Genomic DNA isolated from B. halodurans C-125 was used as the template for PCR amplification of halA1, halA2, halM1, and halM2. Each gene was cloned into the appropriate pET vector to generate an Nterminal hexa-histidine fusion construct. The halA genes were overexpressed in Escherichia coli and the corresponding peptides purified to homogeneity as described for other lantibiotic prepeptides (6) . Similarly, the halM genes were overexpressed in E. coli and the corresponding proteins purified to homogeneity by immobilized metal affinity chromatography, resulting in proteins that were Ͼ90% pure.
Purified HalA1 and HalA2 were incubated together with purified HalM1 and HalM2 in an assay mixture containing TCEP [Tris(2-carboxyethyl)phosphine hydrochloride], MgCl 2 , and ATP (6, 20) and then subjected to MALDI-MS. Incubation of the prepeptides with both modification enzymes resulted in the 3-fold dehydration of HalA1 and the 7-fold dehydration of HalA2 (Fig. 2) . Based on the number of Ser͞Thr residues in the proposed structural regions of HalA1 and HalA2 ( Fig. 1 ), HalA1 underwent three of four possible dehydrations whereas HalA2 was dehydrated at seven of eight possible residues. These results are consistent with the haloduracin peptides isolated from the producer strain whose masses correspond to the same number of dehydration events for each peptide.
The specificity of each enzyme was examined next. Incubation of HalA1 with HalM1 resulted in three dehydrations (Fig. 6A , which is published as supporting information on the PNAS web site), whereas incubation of HalA2 with HalM2 generated a species that was dehydrated 7-fold (Fig. 6B) . Incubation of HalA1 with HalM2 or HalA2 with HalM1 did not result in modified peptide in either case, suggesting that each HalM enzyme can dehydrate one but not both HalA peptides (data not shown). These data also rule out the possibility that a complex involving both peptides and͞or both proteins is required for activity or that the two enzymes act sequentially on each substrate. We examined the activity of HalM1 with HalA1 in the presence of HalA2 as well, and found that addition of the non-substrate peptide does not seem to inhibit modification of the true peptide substrate. Similar results were observed for HalM2 with HalA2 in the presence of HalA1 (data not shown). 
Iodoacetamide (IAA) Modification of the Haloduracin Peptides.
The mass spectra recorded of the HalM assays demonstrate efficient dehydration activity but cannot detect cyclization activity because no change in mass occurs in this step. To test for cyclization activity, the substrates and products were monitored for the presence of free cysteines by alkylation with IAA after treatment with a reducing agent to assure cysteines would be available for reaction. Reaction with iodoacetamide results in the addition of a carbamidomethyl group to each free cysteine, translating to an increase in mass by 57 Da. The authentic Hal␣ and Hal␤ peptides isolated from B. halodurans C-125 were first subjected to IAA modification. Hal␣ displayed two adducts as judged by mass spectrometry (Fig. 3A) . Adduct formation depended on prior treatment with a reductant, suggesting that two Cys residues were tied up in a cystine linkage under nonreducing conditions. Hal␤ did not undergo adduct formation under all conditions tested, consistent with each Cys residue of this peptide being involved in a MeLan or Lan ring (Fig. 3A) .
To evaluate the importance of the disulfide in Hal␣, the bioactivity of Hal␣ and Hal␤ after reduction and chemical modification with iodoacetamide was evaluated after removal of excess iodoacetamide by using thiopropyl Sepharose resin. The reduced peptides and the products containing two (Hal␣) or zero (Hal␤) adducts were then spotted against the indicator strain, where they exhibited zones of growth inhibition comparable to the wild-type peptides (data not shown).
To compare the ring structures of the haloduracin products produced in vitro with the peptides isolated from the producing strain, the products of the HalM assays were also treated with iodoacetamide and analyzed by MALDI-TOF MS. The mass of HalA1 after modification by HalM1 was increased by 116 Da indicating two adducts (Fig. 7 , which is published as supporting information on the PNAS web site). The mass of HalA2 modified by HalM2 remained unchanged under the alkylation conditions tested, consistent with the absence of free Cys residues. These results are in agreement with the chemical modification of the wild-type peptides, indicating that the HalM enzymes carried out the in vitro cyclization reaction in the same manner as in vivo.
Tests for the Presence of a 2-Oxobutyryl Group. The HalA2 peptide has sequence homology with the ␤-prepeptide of plantaricin W (PlwA␤) and the LtnA2 peptide of lacticin 3147. Both of the mature peptides of these lantibiotics are thought to contain a 2-oxobutyryl group at their N terminus (17, 21) , resulting from spontaneous hydrolysis of an N-terminal Dhb. The position of removal of the leader peptide deduced from the mass of Hal␤ as well as its amino acid sequence suggests it might also contain a 2-oxobutyryl residue at its N terminus after proteolysis. To investigate this possibility, the peptide was first reacted with 1,2-diaminobenzene in sodium acetate buffer, which should remove the oxobutyryl group (21, 22) . Analysis by MALDI-TOF, however, did not show any change in the mass of the Hal␤ peptide (Fig. 8A , which is published as supporting information on the PNAS web site). A control reaction with a synthetic peptide 2-oxobutyryl-Ala-Trp-Pro-Ser did show the expected reaction under identical conditions suggesting that Hal␤ does not contain an ␣-keto amide (Fig. 8B) . In another experiment, rather than removing the 2-oxobutyryl group, the peptide was reacted with benzoyl hydrazine, which should result in a hydrazone adduct if a ketone group were present. However, no adduct was obtained with Hal␤ whereas the control peptide did show the expected increase in mass because of hydrazone formation (⌬m ϭ ϩ118 Da) (Fig. 9 , which is published as supporting information on the PNAS web site). Finally, the Hal␣ and Hal␤ peptides were analyzed by high resolution Fourier Transform mass spectrometry (23) 3B ) that clearly showed that, in Hal␤, Thr-1, Thr-2, Thr-7, and Ser-11 are dehydrated and that the one Ser͞Thr residue that is not dehydrated must be among Thr-17, Thr-18, Thr-21, and Ser-22.
Engineering of a Factor Xa Cleavage Site into the HalA Peptides. The biological activity of lantibiotic peptides depends upon the formation of the correct ring structures (24) (25) (26) (27) (28) and the removal of the N-terminal leader sequence of the modified peptides (5, 6) . To investigate the biological activity of the haloduracin peptides prepared in vitro, the leader sequence of each product must therefore be removed. We developed a peptide engineering method to achieve this goal. The last four amino acid residues of each peptide immediately N-terminal to the cleavage site (as deduced from authentic Hal␣ and Hal␤) were replaced with the Factor Xa recognition sequence. Thus, by using molecular biology methods the sequence IEGR was introduced instead of residues 38-41 (VNGA) of HalA1 and residues 32-25 (VHAQ) of HalA2. In this manner, the posttranslationally modified peptide after digestion would correspond to the native mature products.
The HalA peptides containing the Factor Xa cleavage site were overexpressed as hexa-histidine fusion proteins and purified. HalA1-Xa (HalA1 containing the cleavage site) was incubated with HalM1 to generate a 3-fold dehydrated species and HalA2-Xa incubated with HalM2 resulted in a 7-fold dehydrated species as judged by MALDI-TOF MS (data not shown). The results are consistent with the wild-type peptide data, demonstrating that substitution of four residues in the leader sequence of each peptide did not alter the activity of the HalM enzymes. These findings are consistent with detailed studies on the activity of lacticin 481 synthetase (LctM) with mutants of its substrate LctA in which the leader peptide could be altered by mutagenesis without loss of LctM activity (G. C. Patton, L.E.C., and W.A.v.d.D., unpublished data).
After HalM modification, each peptide was subjected to proteolysis by Factor Xa. Application of the proteolyzed samples to the haloduracin sensitive strain L. lactis CNRZ 117 resulted in a zone of inhibition comparable to that produced by Hal␣ and Hal␤ isolated from B. halodurans (Fig. 4) . This zone depended on the addition of both modified peptides. When either peptide was spotted separately, no inhibition was observed.
Discussion
Haloduracin was identified by using bioinformatics rather than isolation from natural sources, an example of using the available genome sequences for discovery of two-component lantibiotics. The possibility that B. halodurans C-125 produced a lantibiotic was recognized during its genome sequencing as the genes were annotated as mersacidin and cytolysin precursors. We show conclusively that these peptides are part of a two-component system. Including haloduracin, seven two-component lantibiotics have now been documented (10, 11, 17, 18, 29, 30) . Interestingly, by searching the nonredundant database for homologs to the haloduracin peptides we discovered another gene cluster in Bacillus lichenformis that encodes two prepeptides, two modification enzymes, and several additional transport, immunity, and regulation proteins involved in lantibiotic biosynthesis. The identification of four systems in the past year (refs. 29 and 30, and this work) suggests that two-component lantibiotics may be more common than previously realized.
In Fig. 5 we propose structures for the two fully processed haloduracin peptides that are consistent with mass spectrometric and structural characterization data presented herein, and with structural precedence in peptides from other systems. Based on the high accuracy mass spectrum of Hal␣, HalA1 undergoes three dehydrations and the N-terminal leader sequence is removed after the anticipated proteolytic cleavage sequence GA. The resulting product retains one unmodified Ser residue that we assign to position 67 as the other three Ser͞Thr residues are involved in highly conserved Lan͞MeLan ring structures (Fig.  1) . The HalA1 structural peptide contains more Cys residues than Ser͞Thr and hence not all cysteines can be engaged in Lan͞MeLan rings. The formation of two IAA adducts only after pretreatment with reductants strongly suggests that two cysteines are present in a cystine linkage in the isolated peptide. Cys-42 and Cys-49 are assigned to be involved based on similarity to Plw␣. Hal␣ is only the third example of a lantibiotic in which Cys residues are present as a disulfide, with sublancin and Plw␣ being other examples (17, 31) . As with plantaricin W (17), the oxidation state of these two Cys residues does not seem to be crucial for biological activity, because reduction and even alkylation with IAA did not abolish antimicrobial activity. The reason for their conservation in these two systems is therefore not understood. The three remaining cysteines are believed to form one Lan and two MeLan rings with the same connectivity as confirmed (21) or proposed for all other known two-component lantibiotics ( Fig. 1) (17, 18, 29, 30) . Importantly, the six-aminoacid-containing MeLan B-ring in Hal␣, which is believed to be important for lipid II binding in mersacidin's C-ring (32) , is conserved including the invariant and essential Glu within this ring (33) . This MeLan ring is also found in the ␣͞A1-peptides of lacticin 3147 (21), plantaricin W (17), staphylococcin C55 (18), Smb (29) , and BHT-A (30), as well as in the A-ring of the lacticin 481 subgroup of single component lantibiotics (3) .
The accurate mass for Hal␤ isolated from B. halodurans C-125 is consistent with 7-fold dehydration of the HalA2 prepeptide and cleavage of the leader peptide C-terminal to Gln-41. As for Hal␣, the mass data indicate that Hal␤ contains one unmodified Ser͞Thr residue, assigned to Thr-18 based on structural similarity with Ltn␤ of lacticin 3147 as well as the FTMS͞MS data that show the unmodified residue to be located in the segment spanning residues 16-24. Proteolytic processing after Gln-41 of HalA2 would result in Dhb42 of HalA2 occupying the Nterminal position of Hal␤ upon removal of the leader peptide. Eneamines are unstable in aqueous solutions and undergo spontaneous and rapid hydrolysis to the corresponding ketone, resulting in a 2-oxobutyryl residue instead of a Dhb (34) . Alternatively, if HalM2 catalyzes the formation of an N-terminal MeLan by reaction of Cys-46 with Dhb42 of the prepeptide (Dhb1 and Cys-5 in mature Hal␤), Hal␤ would not have an N-terminal Dhb upon proteolysis and hence no ␣-keto amide would be formed. The IAA alkylation experiments clearly show that Cys-5 of Hal␤ is indeed involved in a Lan or MeLan because no free Cys is present. Furthermore, three independent methods provided evidence against an N-terminal 2-oxobutyryl group, confirming that HalM2 forms a MeLan between residues 42 and 46 of HalA2. An alternative possibility that would result in the absence of the 2-oxobutyryl group is that Thr-42 is not dehydrated resulting in Thr-1 at the N terminus of Hal␤ after proteolysis. However, this model is inconsistent with the MS͞MS data because the masses of a series of fragment ions (b 5 , b 6 , b 7 , b 8 , and b 15 ; Fig. 3B ) clearly indicate the dehydration of Thr-1 in Hal␤. Unlike Cys-5, the remaining three cysteines in Hal␤ are conserved in the ␤͞A2 peptides of lacticin 3147, plantaricin W, and staphylococcin C55, and hence their involvement in the Lan and MeLan rings shown in Fig. 5 is strongly supported. Indeed the fragment ions observed are fully consistent with the proposed rings of Hal␤, as is the lack of fragmentation in the segments spanning residues 1 and 5, 11 and 15, and 16-24 (6) .
The mass data demonstrate that the cleavage site for the leader peptide of HalA2 is not at the predicted position as the LanT protease domains typically process their substrates at a double Gly recognition motif; for HalA2 this cleavage signal would have been between Ser-35 and Gly-36 ( Fig. 1) . A similar observation has been reported for the two-component systems plantaricin W and cytolysin, in which the peptide undergoes additional proteolytic processing beyond the removal of the leader sequence (10, 17) . In cytolysin the additional proteolysis by CylA has been shown to be necessary for biological activity (10) . At this time no CylA homologs have been located in the genome of B. halodurans C-125. Similarly, no homologs of the dehydrogenase LtnJ that converts dehydroalanine into D-Ala residues in lacticin 3147 (35) have been found. The lack of D-Ala residues is also confirmed by the high-resolution mass data that readily would have detected the additional 2 Da for each such structure. Indeed the stretch of amino acids in which the D-Ala residues are located in Ltn␣͞␤ does not contain a Ser or Thr in Hal␣͞␤ (Fig. 1) . The genome of B. halodurans C-125 was also searched for homologs of the thiol-disulfide oxidoreductase BdbB that introduces the disulfide into the lantibiotic sublancin (36) . One gene (accession number NC002570) was identified but unlike bdbB, it was not located in the lantibiotic biosynthetic gene cluster in B. halodurans C-125.
The successful cloning, heterologous overexpression in E. coli, and purification of HalA1, HalA2, HalM1, and HalM2 provide an in vitro synthesis of a two-component lantibiotic. In addition, the mature haloduracin peptides were prepared after removal of the leader peptide at an engineered Factor Xa cleavage site. The biological activity displayed by these mature products depended on the presence of both modified peptides in the bioassay. Ltn␣ of lacticin 3147 and BHT␣ exhibit low level antibacterial activity by themselves, presumably by weak binding to lipid II (12, 30) . It is possible that Hal␣ may also demonstrate biological activity at higher concentrations, but so far we have been limited in the accessible concentrations of in vitro product because of its poor solubility.
The in vitro reconstitution opens the door to new, intriguing possibilities involving antimicrobial peptide design and engineering because the therapeutic potential of two-component systems is very high (37) . The in vitro biosynthesis system will allow detailed investigation of the substrate specificity of each individual LanM protein as site directed mutants are readily and rapidly accessible. Evaluation of substrate specificity in vitro has certain advantages over in vivo methods for a complex system like lantibiotic biosynthesis (3). In particular, when a lantibiotic producing strain shows low or no bioactivity after mutation of the substrate peptide, this result may imply the original residue was critical for biological activity, or alternatively it may be due to failure of the biosynthetic proteins (dehydratase, cyclase, or protease), poor expression of the mutant substrates, inability of the wild-type transport proteins to secrete the processed mutants, breakdown of the analog products, or potential toxicity of the nonnatural products to the producing strain because of non-recognition of the mutants by the innate immunity proteins. Although in vitro methods have their own disadvantages regarding cost of protein purification and scalability, the substrate specificity of the biosynthetic proteins can be examined in a much more controlled fashion (28) , and improved lantibiotic variants thus identified can be invaluable starting points to subsequently engineer and optimize an in vivo production system. Future studies will therefore concentrate on the generation of haloduracin analogs.
Materials and Methods
General materials and protocols for protein purification, cloning, and assays for the 2-oxobutyryl group, are provided in
